^
Association details:
Biomarker:EGFRvIII mutation
Cancer:Glioblastoma
Drug Class:EGFRvIII-targeted CAR-T immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma

Excerpt:
EGFRvIII-directed CAR T cells were also able to control tumor growth in xenogeneic subcutaneous and orthotopic models of human EGFRvIII(+) glioblastoma.
DOI:
10.1126/scitranslmed.aaa4963